Abstract

IntroductionFocal adhesion kinase (FAK) controls cell growth and survival downstream of integrin-matrix receptors. Upon adhesion loss or FAK inhibition, FAK can translocate to the nucleus. The nucleolus is a non-membrane nuclear structure that regulates ribosome biogenesis and cell proliferation. Nucleostemin (NS), a nucleolar-localized protein, modulates cell cycle progression, stemness, and three-dimensional tumor spheroid formation. The signaling pathways that regulate NS levels in tumors remain undefined.MethodsHuman breast carcinoma cells were evaluated for growth in culture (adherent and anchorage-independent spheroid) and as orthotopic tumors. FAK signaling was evaluated by pharmacological FAK inhibitor addition (PF-271, IC50 ~ 0.1 μM) and by small hairpin RNA (shRNA) knockdown followed by re-expression of FAK wildtype (WT) or a kinase-dead (KD, K454R) FAK point mutant. Immunoblotting was used to evaluate FAK, NS, nucleolar phosphoprotein B23, and nucleolin levels. Total and phosphospecific antibody imunoblotting were used to detect changes in FAK, Akt kinase (Akt also known as protein kinase B), and 4E-binding protein 1 (4E-BP1) phosphorylation, a translation repressor protein and target of the mammalian target of rapamycin (mTOR) complex. Immunohistochemical, co-immunoprecipitation, and cellular fractionation analyses were used to evaluate FAK association with nucleoli.ResultsPharmacological (0.1 μM PF-271) or genetic inhibition of FAK activity prevents MDA-MB-231 and 4T1L breast carcinoma growth as spheroids and as orthotopic tumors. FAK inhibition triggers proteasome-mediated decreased NS levels but no changes in other nucleolar proteins such as B23 (nucleophosmin) or nucleolin. Active FAK was associated with purified nucleoli of anchorage-independent cells and present within nucleoli of human invasive ductal carcinoma tumor samples. FAK co-immunoprecipitated with B23 that binds NS and a complex between FAK, NS, Akt, and mTOR was detected. Constitutively-active Akt kinase promoted tumor spheroid growth, stabilized NS levels, and promoted pS65 4E-BP1 phosphorylation in the presence of inhibited FAK. Rapamycin lowered NS levels and inhibited pS65 4E-BP1 phosphorylation in cells with activated Akt-mTOR signaling.ConclusionsFAK signaling occurs in the nucleolus, active FAK protects NS, and Akt-mTOR pathway regulates NS protein stability needed for breast carcinoma spheroid and tumor growth.Electronic supplementary materialThe online version of this article (doi:10.1186/s13058-015-0551-x) contains supplementary material, which is available to authorized users.

Highlights

  • Focal adhesion kinase (FAK) controls cell growth and survival downstream of integrin-matrix receptors

  • focal adhesion kinase (FAK) signaling occurs in the nucleolus, active FAK protects NS, and Also known as protein kinase B (Akt)-mammalian target of rapamycin (mTOR) pathway regulates NS protein stability needed for breast carcinoma spheroid and tumor growth

  • FAK mRNA levels are elevated in approximately 26% of breast tumors, and high FAK protein levels are common in human epidermal growth factor 2 (HER2)-positive [7] and triple-negative tumors [8]

Read more

Summary

Introduction

Focal adhesion kinase (FAK) controls cell growth and survival downstream of integrin-matrix receptors. Breast cancer is one of the most common cancers in women worldwide [1]. It is a heterogeneous disease with differential responses to therapy [2]. Signals generated from transmembrane integrin receptors are one of the molecular drivers of tumor metastasis [5]. Integrins sense changes in extracellular matrix composition and tension and in turn activate focal adhesion kinase (FAK), a 115 kDa cytoplasmic tyrosine kinase [6]. FAK mRNA levels are elevated in approximately 26% of breast tumors, and high FAK protein levels are common in human epidermal growth factor 2 (HER2)-positive [7] and triple-negative tumors [8].

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call